Ignite Creation Date:
2024-05-06 @ 7:07 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05898321
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-06-12
First Post:
2023-02-10
Brief Title:
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone GnRH Analogues or Mifepristone
Sponsor:
Womens Hospital School Of Medicine Zhejiang University
Organization:
Womens Hospital School Of Medicine Zhejiang University
Study Overview
Official Title:
A MulticenterProspective Clinical Trial for Reducing Remaining Submucous Fibroids Volume and Preventing Recurrence by Treating With GnRH Analogues or Mifepristone After Transcervical Resection of Type I-II Myoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TCRM
Brief Summary:
Transcervical resection of myomaTCRM has a good therapeutic effect while the probability of complete resection of type I and II fibroids is only 55 per procedure on average and a significant number of patients have fibroid remainedAt present there is no standardized treatment option for reducing the remaining submucous fibroids volume and preventing its recurrence after TCRMThe present prospectivemulticentrerandomised controlled clinical trial will enrol women after TCRM and treat them with mifepristone10mgor GnRHa360mgfor 3 to 6 monthsinvestigating the effective and cost-effective treatment options after fibroids with TCRMthus to provide evidence and effectual regiments for reducing remaining fibroids volume and preventing its recurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None